Bifidobacterium pseudocatenulatum capsular exopolysaccharide enhances systemic anti-tumour immunity in pre-clinical breast cancer
Price, C. A.; Nicklin, A.; Kujawska, M.; Koev, T. T.; Ilker, N.; Fowler, W. J.; McKee, A. M.; Mitchel, L.; Rowe, M.; Taylor, J. A. G. E.; Benwell, C. J.; Dreger, S. A.; Muller, J.; Hall, L. J.; Robinson, S. D.
Show abstract
Gut microbes have merged as powerful regulators of cancer responses, with Bifidobacterium species and strains playing a key role in promoting anti-tumour immunity. While they represent promising candidates for cancer therapeutics, the specific underlying microbial mechanisms driving their efficacy remains poorly understood. In this study, we demonstrate the broad potential of Bifidobacterium species to inhibit breast cancer progression across multiple pre-clinical mouse models. We identify a novel strain, Bifidobacterium pseudocatenulatum 210, which induces systemic anti-tumour immunity and enhances responses to standard-of-care therapies via its cell surface capsular exopolysaccharide (EPS). B. pseudocatenulatum 210 EPS promotes dendritic cell activation and increases systemic cDC1 infiltration, leading to robust CD8+ T cell-mediated anti-tumour activity. Our findings position Bifidobacterium EPS as a novel class of therapeutic compounds with significant potential for cancer treatment.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Chronic circadian disruption modulates breast cancer cell stemness and their immune microenvironment to drive metastasis in mice 96%
- Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers 96%
- Metformin enhances anti-mycobacterial responses by educating immunometabolic circuits of CD8+ T cells 94%
Similar papers in this journal
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 95%
- CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming 95%
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 95%
Similar papers in this journal
Similar papers in this journal
- An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer 93%
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 93%
- Sodium accumulation in breast cancer predicts malignancy and treatment response 93%
Similar papers in this journal
- Platinum chemotherapy induces lymphangiogenesis in cancerous and healthy tissues that can be prevented with adjuvant anti-VEGFR3 therapy 94%
- GPR15 in colon cancer development and anti-tumor immune responses. 94%
- Modulated TRPC1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach. 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.